Please read the DISCLAIMER at the bottom of the blog.

Rakesh Jhunjhunwala is considered to be the greatest investor in Indian Market. He is supposed to have made Rs 5000 crores by just investing Rs 5000 in Indian Stock Market. Rakesh Jhunjhunwala guru mantra to be successful in stock market is as enumerated below:

(a) He advises people to become interested in a stock when none is interested in the same stock. As per him BUY RIGHT & HOLD TIGHT for years to come. He has been holding few stocks for last 10 years and he is still minting money from those stocks.

(b) He further advises that one should not follow big investors blindly as their risk profile and long term goals with time frame may be difficult to be followed by retail investor.

(c) Market is supreme and every thing is reflected in the price and thus their is no point in fighting the trend as market is always right.

(d) One should be able to create a balance between the fear and greed.

(e) As per his words one has to learn the stock market trading as none can teach the market as stock market experience is the best teacher.

Thus follow Rakesh Jhunjhunwala advice in stock market, BE PATIENT and grow big like Warren Buffet or this iconic man from Dalaal Street.

If you subscribe to this blog with your email, you will get the post right in your INBOX moment it is posted on this blog. Do remember to activate the subscription in your email. GOOD LUCK.

Tuesday, June 1, 2010

New R&D unit coming up at Lupin to develop products for emerging markets

Domestic drug major Lupin, which recently restructured its new drug research programmes, will set up a research and development (R&D) centre to exclusively develop generic drug products for the emerging markets in Latin America, Africa and Australia.

To employ 50 to 60 people, it is expected to be ready in Aurangabad in three months, said Nilesh Gupta, group president and executive director. Lupin currently has an R&D team of 700-plus scientists.

The new centre would allow Lupin to file product dossiers for marketing approvals in all emerging nations. The centre will also cater to Japan. Lupin’s business in that country currently comes through its subsidiary there, Kyowa Pharmaceuticals.

The attempt will be to get some products from Lupin also registered in Japan to augment its product basket. Kyowa has its own R&D and manufacturing facility in Japan.

The parallel research facility will allow entry into newer markets without diluting the current focus of Lupin’s R&D team to make regulatory filings in the US and European region. Lupin had filed a record 37 product registration filings and 19 bulk drug or raw material registration filings with the US Food and Drug Administration during 2009-10. Fourteen regulatory filings were made with European authorities during the same period.

The product registration will form the basis of Lupin’s expansion plans in these regions. The company is on the lookout for acquisitions in countries like Brazil and Mexico to build marketing muscle to promote its branded generics. “Once the stage is set for new product launches, we will evaluate how to develop a marketing network in these countries,” said Gupta.

Most of Lupin’s factories are operating at over 90 per cent capacity. New facilities – its Special Economic Zone at Indore being a major location for future production centres – are expected to be in tune with growth targets.

“We will not set up idle capacities. Our manufacturing locations will keep adding product lines as and when required. We have decided to introduce one new therapeutic area each year. Addition of dedicated manufacturing facilities will happen as volumes go up in each of these categories. We have been spending Rs 400-500 crore annually during the last three years towards capacity expansion. This investment will continue for some more years,” said Gupta.

He said the company had completely restructured its new drug research programmes. If the earlier research was focused mainly on developing herbal-based drugs and known molecules, the focus now was to develop unique first-in-class drugs (new ones which other companies aren’t trying to develop). The company would look at out-licensing these products to multinational drugmakers, he said.

Just pay $1 to Claim $4,276 Internet System from world’s #1 internet wealth expert for one month. Limited Offer!
Over 55,000 satisfied customers worldwide!


DISCLAIMER: The author is not a registered stockbroker nor a registered advisor and does not give investment advice. His comments are an expression of opinion only and should not be construed in any manner whatsoever as recommendations to buy or sell a stock, option, future, bond, commodity, index or any other financial instrument at any time. While he believes his statements to be true, they always depend on the reliability of his own credible sources. The author recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction, before making any investment decisions, and that you confirm the facts on your own before making important investment commitments.

Website hit counters